Latest News and Press Releases
Want to stay updated on the latest news?
-
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of...
-
The Marquie Group Joins Forces with City of Hope to Combat Triple-Negative Breast Cancer
-
TMGI subsidiary Music of Your Life launches syndicated radio program as company continues focuse on cancer awareness.
-
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
-
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
-
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple...
-
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing...
-
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
-
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
-
New York, USA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market -...